Pro-Pharmaceuticals, Inc. (Amex: PRW), announced that new data of 14 end-stage colorectal cancer patients from its Phase II trial showed that DAVANAT® extended median survival by more than six months. The Company tracked these patients and gathered data after they left the trial. The patients entered the trial with disease that progressed despite previously being treated with standard chemotherapies and biologics such as AVASTIN® and/or ERBITUX®.

More: continued here

This entry was posted on Wednesday, February 13th, 2008 at 12:02 pm and is filed under Cancer. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.